Cas:7267-28-9 2-Benzothiazolecarboxylicacid,4-methoxy-,methylester(7CI,8CI,9CI) manufacturer & supplier

Chemical Name:2-Benzothiazolecarboxylicacid,4-methoxy-,methylester(7CI,8CI,9CI)

CAS.NO:7267-28-9

Synonyms:4-Methoxy-2-methoxycarbonyl-benzthiazol;4-methoxy-benzothiazole-2-carboxylic acid methyl ester;4-methoxy-2-iodophenol;Phenol,2-iodo-4-methoxy

Molecular Formula:C₁₀H₉NO₃S

Molecular Weight:223.24800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:76.66000

Exact Mass:223.03000

LogP:2.09150

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Methoxy-2-methoxycarbonyl-benzthiazol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Phenol,2-iodo-4-methoxy physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Methoxy-2-methoxycarbonyl-benzthiazol Use and application,4-methoxy-2-iodophenol technical grade,usp/ep/jp grade.

Related News: The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. 2-Benzothiazolecarboxylicacid,4-methoxy-,methylester(7CI,8CI,9CI) manufacturer One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 2-Benzothiazolecarboxylicacid,4-methoxy-,methylester(7CI,8CI,9CI) supplier The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. 2-Benzothiazolecarboxylicacid,4-methoxy-,methylester(7CI,8CI,9CI) vendor Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development. 2-Benzothiazolecarboxylicacid,4-methoxy-,methylester(7CI,8CI,9CI) factory Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.